Anavex Life Sciences (AVXL) Reports Q3 Loss of $0.06/Share; No Longer Under SEC Investigation

Anavex Life Sciences (NASDAQ: AVXL) reported Q3 EPS of ($0.06), versus ($0.22) reported last year.

The SEC staff recently advised Company’s legal counsel that the staff did not intend to recommend enforcement action by the Commission against the Company in connection with the investigation previously described in the Company’s 2015 Report on Form 10-K.

For earnings history and earnings-related data on Anavex Life Sciences (AVXL) click here.

You May Also Be Interested In

• Robinhood prices $2B convertible notes offering due 2029
• Dorian LPG orders new VLGC, plans to sell three vessels
• Ligand prices $625M convertible notes due 2031 at 0% interest